| scholarly article | Q13442814 |
| editorial | Q871232 |
| P2093 | author name string | Michael S. Ewer | |
| Steven M. Ewer | |||
| P2860 | cites work | Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes | Q24308695 |
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Risk factors for doxorubicin-induced congestive heart failure | Q28328220 | ||
| Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized | Q31089499 | ||
| Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy | Q33183838 | ||
| Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation | Q33647686 | ||
| Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. | Q42626922 | ||
| Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall | Q43180234 | ||
| Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial | Q43250043 | ||
| 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. | Q53467043 | ||
| Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre | Q61624905 | ||
| Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity | Q81698731 | ||
| P433 | issue | 25 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3901-3904 | |
| P577 | publication date | 2010-08-02 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction | |
| Troponin I Provides Insight Into Cardiotoxicity and the Anthracycline-Trastuzumab Interaction | |||
| P478 | volume | 28 |
| Q51760757 | Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. |
| Q36575695 | Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways |
| Q51739297 | Cardiac complications of chemotherapy: role of biomarkers. |
| Q38091377 | Cardiac toxicity of anticancer agents |
| Q37663263 | Cardiotoxicity Following Cancer Treatment |
| Q38473331 | Cardiotoxicity of anticancer treatments |
| Q37967508 | Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology |
| Q38982196 | Combination of rituximab and nonpegylated liposomal doxorubicin (R-NPLD) as front-line therapy for aggressive non-Hodgkin lymphoma (NHL) in patients 80 years of age or older: a single-center retrospective study. |
| Q47131512 | Effects of treatment with chemotherapy and/or tamoxifen on the biomarkers of cardiac injury and oxidative stress in women with breast cancer |
| Q90202998 | Elevated Cardiac Troponin in Clinical Scenarios Beyond Obstructive Coronary Artery Disease |
| Q38842771 | From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. |
| Q92618978 | Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients |
| Q26783121 | How can clinical research help our understanding of trastuzumab-related cardiotoxicity? |
| Q38546114 | Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. |
| Q90461158 | MicroRNAs in Cancer Treatment-Induced Cardiotoxicity |
| Q46253112 | Oxidative Stress and Cellular Response to Doxorubicin: A Common Factor in the Complex Milieu of Anthracycline Cardiotoxicity. |
| Q35132483 | Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial |
| Q50146298 | Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production |
| Q28087776 | Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs |
| Q36511593 | Replacement of conventional doxorubicin by pegylated liposomal doxorubicin in standard RCHOP chemotherapy for elderly diffuse large B-Cell lymphoma: a retrospective study in China |
| Q35872865 | S100A1 as a Potential Diagnostic Biomarker for Assessing Cardiotoxicity and Implications for the Chemotherapy of Certain Cancers |
| Q100418466 | The role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and Cardio-Oncology Council of the European Society of Cardiology |
Search more.